User menu

HIV-1 proviral resistance mutations: usefulness in clinical practice.

Bibliographic reference Kabamba-Mukadi, Benoît ; Duquenne, Armelle ; Henrivaux, P. ; Musuamba Tshinanu, Flora ; Ruelle, Jean ; et. al. HIV-1 proviral resistance mutations: usefulness in clinical practice.. In: HIV Medicine, Vol. 11, no. 8, p. 483-492 (2010)
Permanent URL http://hdl.handle.net/2078.1/29679
  1. 1  Boden D , Hurley A , Zhang L et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999; 282: 1135-1141.
  2. 2  Little SJ , Daar ES , D'Aquila RT et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999; 282: 1142-1149.
  3. 3  Vercauteren J , Derdelinckx I , Sasse A et al. Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. AIDS Res Hum Retroviruses 2008; 24: 355-362.
  4. 4  Wensing AMJ , Vercauteren J , van de Vijver DA et al. for the SPREAD Programme. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008; 22: 625-635.
  5. 5  Angarano G , Monno L , Appice A et al. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts [Letter]. AIDS 1994; 8: 1013-1014.
  6. 6  Yerly S , Vora S , Rizzardi P et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15: 2287-2292.
  7. 7  Conlon CP , Klenerman P , Edwards A et al. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis 1994; 169: 411-415.
  8. 8  Hecht FM , Grant RM , Petropoulos CJ et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998; 339: 307-311.
  9. 9  Ippolito G , Del Poggio P , Arici C et al. Transmission of zidovudine-resistant HIV during a bloody fight [letter]. JAMA 1994; 272: 433-434.
  10. 10  Imrie A , Beveridge A , Genn W et al. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine: Sydney Primary HIV Infection Study Group. J Infect Dis 1997; 175: 1502-1506.
  11. 11  Veenstra J , Schuurman R , Cornelissen M et al. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. Clin Infect Dis 1995; 21: 556-560.
  12. 12  Yerly S , Kaiser L , Race E et al. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999; 354: 729-733.
  13. 13  Baxter JD , Mayers DL , Wentworth DN et al. Final results of CPCRA 046: a pilot study of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Antivir Ther 1999; 4 (Suppl 1): 43.
  14. 14  Baxter JD , Mayers DL , Wentworth DN et al. A randomized study on antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing antiretroviral therapy. AIDS 2000; 14: F83-F93.
  15. 15  Clevenbergh P , Durant J , Halfon P et al. Persisting long-term benefit of antiretroviral genotypic guided treatment for HIV-infected patients failing HAART. Antivir Ther 1999; 4 (Suppl 1): 42.
  16. 16  Cohen C , Hunt S , Sension M et al. for the VIRA3001 Study Team. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16: 579-588.
  17. 17  Tural C , Ruiz L , Holtzer C et al. Clinical utility of HIV-1 genotyping and expert advice: the Havanna trial. AIDS 2002; 16: 209-2018.
  18. 18  Hirsch MS , Günthard HF , Schapiro JM et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an international AIDS society-USA panel. Clin Infect Dis 2008; 47: 266-285.
  19. 19  Clumeck N , Pozniak A , Raffi F and the EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008; 9: 65-71.
  20. 20  Grant RM , Hecht FM , Warmerdam M et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288: 181-198.
  21. 21  Hammer SM , Saag MS , Schechter M et al. Treatment for adult HIV infection, 2006 recommendations of the international AIDS society-USA panel. JAMA 2006; 296: 827-843.
  22. 22 The Euro Guidelines Group for HIV resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001; 15: 309-320.
  23. 23  Vandamme AM , Sonnerborg A , Ait-Khaled M et al. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004; 9: 829-848.
  24. 24  Wensing AMJ , van de Vijver DA , Angarano G et al. Prevalence of drug resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192: 958-966.
  25. 25  Descamps D , Flandre P , Calvez V et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. JAMA 2000; 283: 205-211.
  26. 26  Havlir DV , Hellmann NS , Petropoulos CJ et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000; 283: 229-234.
  27. 27 International AIDS Society-USA Resistance Mutations Project Panel. Update of the drug resistance mutations in HIV-1. Available at http://www.iasusa.org/resistance_mutations (accessed 3 February 2006).
  28. 28  Riva E , Pistello M , Narciso P et al. Decay of HIV type 1 DNA and development of drug-resistant mutants in patients with primary HIV type 1 infection receiving highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2001; 17: 1599-1604.
  29. 29  Chew CB , Potter SJ , Wang B et al. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J Clin Virol 2005; 33: 206-216.
  30. 30  Bona I , Gibellini D , Borderi M et al. Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. J Clin Virol 2007; 38: 313-320.
  31. 31  Wang YM , Dyer WB , Workman C et al. Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption (STI) and non-interrupted HAART. Curr HIV Res 2007; 5: 235-250.
  32. 32  Ghosn J , Pellegrin I , Goujard C et al. for the French PRIMO Cohort Study Group (ANRS CO 06). HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006; 20: 159-170.
  33. 33  Usuku S , Noguchi Y , Sakamoto M et al. Analysis of a long-term discrepancy in drug-targeted genes in plasma HIV-1 and PBMC HIV-DNA in the same patient. Jpn J Infect Dis 2006; 59: 122-125.
  34. 34  Pabsta R , Rosenbergb YJ. Interpreting data on lymphocyte subsets in the blood of HIV patients - organ distribution, proliferation and migration kinetics are critical factors. Pathobiology 1998; 66: 117-122.
  35. 35  Schnuda ND. Circulation and migration of small blood lymphocytes in the rat. I. Kinetics of lymphocyte circulation in the lymphoid organs. Am J Pathol 1978; 93: 623-638.
  36. Girard, VIH (2001)
  37. 37  Schmit JC , Cogniaux J , Hermans P et al. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis 1996; 174: 962-968.
  38. 38 The Stanford mutation list version 6.0.3. Available at http://hivdb.stanford.edu/pages/algs/sierra_mutation.html (accessed 1 September 2009).
  39. 39  Landis JR , Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
  40. 40  Noë A , Plum J , Verhofstede C. The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance. J Antimicrob Chemother 2005; 55: 410-412.